Dyslipidemia in Dialysis Patients

Seminars in Dialysis

Volumn 28, Issue 4, 2015, Pages 345-353

  Qunibi, Wajeh Y ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

COMPLICATION; DYSLIPIDEMIAS; HUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84935682961     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12375     Document Type: Article

References (62)

1. U.S. Renal Data System: USRDS 2013 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112, 1998
3. Foley RN, Collins AJ: End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 18(10):2644-2648, 2007
4. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80(6):572-586, 2011
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108:2154-2169, 2003
6. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356:147-152, 2000
7. Coll B, et al.: Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrol Dial Transplant 25:3017-3025, 2010
8. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S: High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 16:1141-1148, 2005
9. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357, 1998
12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
13. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005
14. Epstein M, Vaziri ND: Role of statins in the management of dyslipidemia of chronic kidney disease; Current concepts and emerging treatment paradigms. Nat Rev Nephrol 8(4):214-223, 2012
15. Kassimatisa TI, Goldsmith DJA: Statins in chronic kidney disease and kidney transplantation. Pharmacol Res 88:62-73, 2014
16. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32(Suppl 3):S142-S156, 1998
17. Third Report of the National Cholesterol Education Program: (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute. Circulation 106:3143-3420, 2002
18. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
19. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
20. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al.: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18:293-303, 2007
21. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18:304-311, 2007
22. Liu Y, Coresh J, Eustace JA, et al.: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451-459, 2004
23. Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
24. Tonelli M, Isles C, Curhan GC, et al.: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110(12):1557-1563, 2004
25. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2002
26. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-126, 2005
27. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group: K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41: I-IV, S1-91, 2003
28. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84:S207-S210, 2003
29. Wanner C, Krane V, Ruf G, et al.: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 71:S222-S226, 1999
30. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
31. Marz W, Genser B, Drechsler C, et al.: Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6:1316-1325, 2011
32. Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407, 2009
33. Baigent C, Landray MJ, Reith C, et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomized placebo-controlled trial. Lancet 377:2181-2192, 2011
34. Palmer SC, Craig JC, Navaneethan SD, et al.: Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157:263-275, 2012
35. Upadhyay A, Earley A, Lamont JL, et al.: Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157:251-262, 2012
36. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, et al.: Statinsdecrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21, 295 participants. Pharmacol Res 72:35-44, 2013
37. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GFM: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2013(9): CD004289, 2013
38. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H: Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 34:1807-1817, 2013
39. Koya D, Campese VM: Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb 20:407-424, 2013
40. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y: Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6:1112-1120, 2011
41. Shurraw S, Tonelli M: AURORA: is there a role for statin therapy in dialysis patients? Am J Kidney Dis 55:237-240, 2010
42. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1381-1389, 1994
43. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau L-W, McBean M, Murray A, St. Peter W, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen S-C, Dalleska F: United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 53:S1-S374, 2009
44. Drüeke TB, Massy ZA: Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6:723-735, 2010
45. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15:538-548, 2004
46. Parekh RS, Plantinga LC, Kao WH, et al.: The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 74:1335-1342, 2008
47. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
48. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15:329-337, 2002
49. Vaziri ND, Norris KC: Reasons for the lack of salutary effects of cholesterol lowering interventions in ESRD populations. Blood Purif 35(1-3):31-36, 2013
50. Ritz E, Wanner C: Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 19:1065-1070, 2008
51. Kassimatisa TI, Goldsmith DJA: Statins in chronic kidney disease and kidney transplantation. Pharmacol Res 88C:62-73, 2014
52. Wanner C, Krane V: Uremia-specific alterations in lipid metabolism. Blood Purif 20:451-453, 2002
53. Liang K, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 53:626-630, 1998
54. Baigent C, Landray M, Leaper C, et al.: First United Kingdom Heart and Renal Protection (UK-HARP-1) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45:473-484, 2005
55. Landray M, Baigent C, Leaper C, et al.: The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetemibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47:385-395, 2006
56. Kasiske BL, Wanner C, O'Neill WC: An assessment of statin safety by nephrologists. Am J Cardiol 97:82C-85C, 2006
57. Walker DB, Walker TJ, Jacobson TA: Chronic kidney disease and statins: improving cardiovascular outcomes. Current Atheroscler Rep 11:301-308, 2009
58. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol 73:3D-11D, 1994
59. Harper CR, Jacobson TA: Treatment of dyslipidemia in CKD. J Am Coll Cardiol 51:2375-2384, 2008
60. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease. Kidney Int Suppl 3: 259-305, 2013
61. Ichihara A, Hayashi M, Ryuzaki M, et al.: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17:1513, 2002
62. Chang JW, Yang WS, Min WK, et al.: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39:1213, 2002